Publications by authors named "Marc Ferrante"

Claim this Profile

Mentions over time

Mentions by platform

Video Views

272

Total Likes

3

Extended Reach

34,949

Social Features

4
I
Impact of endoscopy system, high definition, and virtual chromoendoscopy in daily routine colonoscopy: a randomized trial.
Philip Roelandt, Ingrid Demedts, Hilde Willekens, Talat Bessissow, Lieve Braeye, Georges Coremans, Pieter-Jan Cuyle, Marc Ferrante, Anne-Marie Gevers, Martin Hiele

Endoscopy· March 2019

Videos about Article: user

1 2 3

View All Article and Social Media Activity
F
FFAR4 drives stem cell fate toward lipid- and iron-storing enterocytes protecting human enteroids from ferroptosis.
Mona Farhadipour, Hui Leng, Theo Thijs, Antoine Dubois, Ellen Deleus, Marc Ferrante

Stem Cell Res Ther· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design and rationale for the VICTRIVA study: A randomized, double-blind, phase 3b study of vedolizumab in combination with upadacitinib in Crohn's disease.
Silvio Danese, Bruce E Sands, Brian G Feagan, Vipul Jairath, Remo Panaccione, Marc Ferrante

Contemp Clin Trials Commun· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multi-stakeholder validation of an evidence-based core set of quality indicators for IBD in Belgium.
Liselotte Fierens, Frank E Rademakers, Peter Bossuyt, Filip Baert, Didier Baert, Marc Ferrante

BMC Health Serv Res· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HER2, HER3, and Mismatch Repair Protein Expression in Stage IV Small Bowel Adenocarcinoma: Results From a Multicenter Series.
Alessandro Vanoli, Tommaso Colella, Paola Parente, Giuseppe De Lisi, Federica Grillo, Marc Ferrante

Mod Pathol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment of PredictSURE IBD Assay in a Multinational Cohort of Patients With Inflammatory Bowel Disease.
Dahham Alsoud, Nurulamin M Noor, Lea Ann Chen, Vivian Abadom, Simon H C Anderson, Marc Ferrante

United European Gastroenterol J· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment discontinuation rates due to lack of efficacy through 1 year of maintenance treatment with vedolizumab or subcutaneous infliximab in patients with inflammatory bowel disease: a systematic literature review and meta-analysis.
Marc Ferrante, Laurent Peyrin-Biroulet, Perttu Arkkila, Alessandro Armuzzi, Jean-Frédéric Colombel

Therap Adv Gastroenterol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimizing the switch from escalated intravenous to subcutaneous infliximab: a population pharmacokinetics-pharmacodynamics study.
Zhigang Wang, Marc Ferrante, Séverine Vermeire, Erwin Dreesen

J Crohns Colitis· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Unravelling the genetic architecture of inflammatory bowel disease multiplex families with rare and common variant polygenic risk scores.
Deborah S Jans, Jana Depovere, Ho-Su Lee, Yasmina Abakkouy, Sara Becelaere, Marc Ferrante

J Crohns Colitis· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Infliximab and Ustekinumab Clearance Better Predict Endoscopic Outcomes Than Trough Concentrations in Crohn's Disease.
Zhigang Wang, Yannick Hoffert, Wei Zhang, Wannee Kantasiripitak, Bram Verstockt, Marc Ferrante

Clin Gastroenterol Hepatol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development and validation of the FR-QoL-29-Dutch (Flemish) Questionnaire and assessment of clinical factors associated with food-related quality of life in a Belgian inflammatory bowel disease population: a cross-sectional study.
Judith Wellens, Livia Guadagnoli, Julie Vanderstappen, Sien Hoekx, Justine Vandaele, Marc Ferrante

BMJ Open Gastroenterol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Gravity of a Unique Subcutaneous Anti-IL23 Induction Regimen.
Judith Wellens, Erwin Dreesen, Marc Ferrante

Gastroenterology· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Five Dietary Emulsifiers on Inflammation, Permeability, and the Gut Microbiome: A Placebo-controlled Randomized Trial.
Judith Wellens, Julie Vanderstappen, Sien Hoekx, Eva Vissers, Martijn Luppens, Marc Ferrante

Clin Gastroenterol Hepatol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gaps between European Crohn's Colitis Organisation quality standards of care and the real world on structure of IBD units across Europe: results from E-QUALITY survey.
Gionata Fiorino, Alissa Walsh, Michel Adamina, Manuel Barreiro-de Acosta, Mariam P Ali, Marc Ferrante

J Crohns Colitis· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
ECCO Topical Review on Pouch Disorders.
Maia Kayal, Gabriele Bislenghi, Michel Adamina, Zaid S Ardalan, Nicolas Avellaneda, MarC Ferrante

J Crohns Colitis· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gaps between European Crohn's and Colitis Organisation quality standards of care and the real world on diagnosis and monitoring inflammatory bowel disease across Europe: results from the E-QUALITY survey.
Gionata Fiorino, Catarina Fidalgo, Michel Adamina, Manuel Barreiro-de Acosta, Mariam P Ali, Marc Ferrante

J Crohns Colitis· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Clinical Effectiveness and Safety of Vedolizumab and Ustekinumab in Biologic-Naïve Patients With Early or Late Crohn's Disease: Results From the EVOLVE Expansion Study.
Britt Christensen, Michael Scharl, Brian Bressler, Zaeem Khan, Yuliya Halchenko, Marc Ferrante

Crohns Colitis 360· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bowel Urgency in Crohn's Disease: Effects of Mirikizumab in a Randomized Controlled Phase 3 Study.
Vipul Jairath, Geert D'Haens, Bruce E Sands, Simon Travis, María Chaparro, Marc Ferrante

Clin Gastroenterol Hepatol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
No Increased Risk of Venous Thromboembolism or Infectious Complications after Janus Kinase Inhibitor Exposure in Patients with Ulcerative Colitis Undergoing Surgery.
Ine De Greef, Gabriele Bislenghi, Isabelle Terrasson, João Sabino, Marc Ferrante

Dig Dis· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Clinical Effectiveness and Safety of Vedolizumab and Ustekinumab in Biologic-Naive Patients With Crohn's Disease By Disease Location: Results from the EVOLVE Expansion Study.
Michael Scharl, Britt Christensen, Brian Bressler, Neil R Brett, Lauren Gianchetti, Marc Ferrante

J Clin Gastroenterol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Ulcerative colitis disease severity affects the speed of symptom relief under filgotinib treatment: a post hoc analysis of the phase 2b/3 SELECTION study.
Masayuki Saruta, Silvio Danese, Yoshie Takatori, Toshihiko Kaise, Christine Rudolph, Marc Ferrante

Intest Res· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Serum extracellular RNAs as a noninvasive approach to differentiate inflammatory bowel disease subtypes: a proof-of-concept study.
Sare Verstockt, João Sabino, Marc Ferrante, Séverine Vermeire, Bram Verstockt

J Crohns Colitis· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Drug tissue concentration and STAT3 modulation as determinants of tofacitinib response in ulcerative colitis.
Bram Verstockt, Dahham Alsoud, Joep van Oostrom, Sare Verstockt, Jeff Smith, Marc Ferrante

J Crohns Colitis· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cooking methods affect advanced glycation end products and lipid profiles: A randomized cross-over study in healthy subjects.
Judith Wellens, Eva Vissers, Anaïs Dumoulin, Sien Hoekx, Julie Vanderstappen, Marc Ferrante

Cell Rep Med· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Development of a Multidisciplinary Care Pathway for Patients with Inflammatory Bowel Disease Before, During and After Pregnancy.
Els De Dycker, Sien Lenie, Michael Ceulemans, Patricia Geens, Tessy Lambrechts, Marc Ferrante

J Clin Med· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Risankizumab Induction and Maintenance Therapy on the Rate of Hospitalization in Patients with Crohn's Disease.
Brian G Feagan, Remo Panaccione, Stefan Schreiber, Edward V Loftus, Laurent Peyrin-Biroulet, Marc Ferrante

Gastro Hep Adv· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis